R&D Overview

Peptide Therapeutics

We are a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. The platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity, selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications. We have successfully utilized the platform to date to identify oral, GI-restricted peptides (PTG-100 and PTG-200) for inflammatory bowel diseases (IBD) and injectable peptides (PTG-300) for rare blood disorders.

Oral, GI-Restricted Peptides PTG-100 and PTG-200 for IBD

We are developing first-in-class oral peptide drugs that specifically target biological pathways that are targeted by marketed injectable antibody drugs. Compared to injectable antibody drugs, oral GI-restricted peptides can potentially offer improved safety due to minimal exposure in the blood compartment, improved convenience and compliance due to oral delivery, and the opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Our product candidates, PTG-100 and PTG-200, are based on this approach, and we believe they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis (UC) and Crohn’s disease (CD).

PTG-300 for β-Thalassemia

PTG-300 is an injectable hepcidin mimetic peptide being developed to treat chronic anemia associated with ineffective erythropoiesis and iron overload in patients with β-Thalassemia. The U.S. Food and Drug Administration (FDA) has granted PTG-300 Orphan Drug and Rare Disease and Fast Track designations for treatment of patients with β-Thalassemia.

Back to top